Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research

This image opens in the lightbox

News provided by

We Market Research

10 Nov, 2023, 15:01 GMT

Share this article

Share toX

Share this article

Share toX

CHICAGO, Nov. 10, 2023 /PRNewswire/ --  According to the latest findings from We Market Research, the oncology drug market is on track to achieve a value of USD 205 billion by the year 2023. Projections indicate that potential fluctuations could drive the market's value to USD 520 billion by 2033, supported by a significant compound annual growth rate (CAGR) of 13.8% expected between 2023 and 2033.

The advent of biosimilars, which represent more affordable alternatives to biologic cancer medications, has broadened patient access to oncology treatments and intensified market competition.

The emergence of biosimilars has ushered in a transformative era within the realm of oncology treatments. These biosimilars, which offer more cost-effective alternatives to biologic cancer medications, have had a profound impact on patient access and market dynamics.

Request Your Sample Report for more insights into the Oncology Drugs Market:

https://wemarketresearch.com/sample-request/oncology-drugs-market/1313

Biosimilars are designed to be highly similar to their reference biologic drugs, not only in terms of structure but also in terms of safety and efficacy. They provide a more budget-friendly option for patients and healthcare systems without compromising on treatment quality. This affordability is a critical factor, especially in cancer care, where the cost of biologic medications can be a significant burden for both patients and healthcare providers.

One of the most significant outcomes of the introduction of biosimilars in the oncology field is the broadening of patient access to cutting-edge treatments. By offering more cost-efficient alternatives, biosimilars ensure that a more extensive and diverse patient population can benefit from the latest advancements in cancer therapy. This inclusivity is essential, as it enables a more significant number of individuals to receive timely and effective treatment, ultimately improving patient outcomes.

Furthermore, the competition that biosimilars inject into the oncology drug market is driving positive change. It encourages innovation, fosters price competition, and compels biologic drug manufacturers to enhance their products and offer more competitive pricing. This competitive environment can lead to lower costs for healthcare systems, making oncology treatments more sustainable and accessible in the long term.

In conclusion, the advent of biosimilars in oncology has not only offered more economical alternatives for patients but has also propelled market competition. As biosimilars continue to gain acceptance, they are expected to play a pivotal role in improving the accessibility of oncology treatments and encouraging ongoing advancements in cancer care. This transformation represents a significant stride in the quest to provide effective and affordable healthcare solutions for individuals battling cancer.

The increasing incidence of breast cancer is broadening the horizons of the oncology drugs market

The escalating prevalence of breast cancer is becoming a defining factor in the ever-expanding landscape of the oncology drugs market. This shift in the healthcare landscape is underpinned by several significant drivers that are transforming the market's dynamics and scope.

Breast cancer, as one of the most commonly diagnosed malignancies among women globally, has garnered substantial attention in the medical community. The rising incidence of breast cancer cases can be attributed to a myriad of factors, including lifestyle changes, environmental influences, genetic predisposition, and the increased adoption of screening and early detection programs. This heightened awareness and early diagnosis are not only extending the lives of affected individuals but also fueling the demand for a wider array of effective oncology drugs.

Additionally, research and development efforts are increasingly dedicated to breast cancer, resulting in a richer pipeline of potential treatments. Clinical trials and collaborations between pharmaceutical companies and research institutions are accelerating the introduction of novel drugs and treatment modalities into the market.

The broader horizons of the oncology drugs market are not solely driven by the pharmaceutical industry but also by the heightened awareness and advocacy of patient groups, healthcare professionals, and government bodies. This collective effort is pushing for more accessible, patient-centered care and a wider array of treatment options for breast cancer patients.

In conclusion, the increasing incidence of breast cancer is playing a central role in the continuous expansion of the oncology drugs market. The focus on breast cancer research and treatment innovations is driving the development of more effective and personalized therapies. As this trend persists, the oncology drugs market will remain at the forefront of advancing patient care and improving outcomes for those affected by this prevalent form of cancer.

Purchase Now to Access Segment-specific Information and uncover Key Trends, Drivers, and Challenges:

https://wemarketresearch.com/purchase/oncology-drugs-market/1313?license=single

Competitive Analysis

The oncology drugs market is dominated by a few large companies, such as Merck & Co., Inc., Novartis International Ag, Amgen, Inc., Bristol-Myers Squibb Company, Astrazeneca Plc, F. Hoffmann-La Roche Ag, Pfizer, Inc., Astellas Pharma Inc., Johnson & Johnson, Abbvie Inc.

There Are Some Of The Recent Developments Of The Oncology Drugs Market:

May 2023 AbbVie Inc. announced the U.S. FDA approval for its EPKINLY, among the only drugs for treatment of patients with relapsed or refractory diffuse large b-cell lymphoma (DLBCL).

March 2023 Pfizer Inc. announced a merger agreement to acquire Seagen, Inc., a global biotechnology company involved in manufacturing cancer medicines. The acquisition would strengthen Pfizer's capabilities and expertise in oncology.

Have a Look at Related Reports of Healthcare & Life Sciences Domain:   

Injectable Cytotoxic Drugs Market

Novel Drug Delivery Systems Market

Inhalation Spray Drugs Market

Erectile Dysfunction Drugs Market

Anti-Neprilysin Drug Market

About We Market Research:

WE MARKET RESEARCH is an established market analytics and research firm with a domain experience sprawling across different industries. We have been working on multi-county market studies right from our inception. Over the time, from our existence, we have gained laurels for our deep rooted market studies and insightful analysis of different markets.

Contact Us:

Mr. Robbin
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: sales@wemarketresearch.com

Logo: https://mma.prnewswire.com/media/2267296/We_Market_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.